Stemline Therapeutics (NASDAQ:STML) Price Target Cut to $8.00 by Analysts at JPMorgan Chase & Co.

Stemline Therapeutics (NASDAQ:STML) had its target price reduced by equities researchers at JPMorgan Chase & Co. from $9.00 to $8.00 in a research report issued to clients and investors on Thursday, BenzingaRatingsTable reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 86.05% from the stock’s current price.

A number of other analysts also recently issued reports on STML. Aegis reissued a “buy” rating and issued a $11.00 target price on shares of Stemline Therapeutics in a research report on Monday. Wedbush reduced their price target on Stemline Therapeutics from $14.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, March 17th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 21st. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, BidaskClub cut Stemline Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, March 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Stemline Therapeutics has a consensus rating of “Buy” and an average price target of $15.56.

NASDAQ:STML traded up $0.06 during trading hours on Thursday, reaching $4.30. The stock had a trading volume of 37,783 shares, compared to its average volume of 970,498. The stock has a 50 day simple moving average of $5.80 and a 200 day simple moving average of $8.74. Stemline Therapeutics has a 12-month low of $3.21 and a 12-month high of $18.22. The stock has a market cap of $223.16 million, a P/E ratio of -2.25 and a beta of 1.44.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Friday, March 13th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.01. Stemline Therapeutics had a negative return on equity of 56.00% and a negative net margin of 177.74%. The business had revenue of $11.83 million during the quarter, compared to the consensus estimate of $11.82 million. As a group, equities research analysts expect that Stemline Therapeutics will post -1.29 earnings per share for the current year.

In related news, CEO Ivan Bergstein sold 24,642 shares of Stemline Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $6.42, for a total transaction of $158,201.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Kenneth Hoberman sold 13,228 shares of Stemline Therapeutics stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $10.37, for a total value of $137,174.36. The disclosure for this sale can be found here. Insiders have sold 125,289 shares of company stock valued at $815,230 in the last three months. 13.10% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of STML. Voya Investment Management LLC lifted its stake in Stemline Therapeutics by 8.2% during the third quarter. Voya Investment Management LLC now owns 17,250 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 1,313 shares during the last quarter. Bank of Montreal Can lifted its stake in Stemline Therapeutics by 48.6% during the fourth quarter. Bank of Montreal Can now owns 5,841 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,909 shares during the last quarter. Rhumbline Advisers lifted its stake in Stemline Therapeutics by 3.5% during the fourth quarter. Rhumbline Advisers now owns 56,322 shares of the biopharmaceutical company’s stock worth $599,000 after purchasing an additional 1,924 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Stemline Therapeutics by 3.1% during the fourth quarter. Victory Capital Management Inc. now owns 70,495 shares of the biopharmaceutical company’s stock worth $749,000 after purchasing an additional 2,133 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Stemline Therapeutics by 1.2% during the fourth quarter. Bank of New York Mellon Corp now owns 185,080 shares of the biopharmaceutical company’s stock worth $1,967,000 after purchasing an additional 2,272 shares during the last quarter. 81.86% of the stock is owned by institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Why is the price target of stocks important?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.